Ares is a seed stage cell therapy development company in the Atlanta, GA area with a focus on the treatment of solid tumors. We were founded on a platform cellular therapy technology based on the presence of CD26, and the proven ability of these cells to mediate significant tumor regression in multiple forms of malignancy.
Our first clinical indication will be mesothelioma using our CD26+ meso-CAR product and we expect to launch our first in human trial in 2024. The widespread expression of mesothelin in solid tumors enables us to move the same construct forward with a clinical pipeline targeting other malignancies such as lung cancer, pancreatic cancer, and ovarian cancer.
